Abstract
The socioeconomic burden of multi-factorial pathologies, such as neurodegenerative diseases (NDs), is enormous worldwide. Unfortunately, no proven disease-modifying therapy is available yet and in most cases (e.g., Alzheimer's and Parkinson's disease) the approved drugs exert only palliative and symptomatic effects. Nowadays, an emerging strategy for the discovery of disease-modifying drugs is based on the multi-target directed ligand (MTDL) design, an innovative shift from the traditional approach one-drug-one-target to the more ambitious one-drug-more-targets goal. Herein, we review the discovery strategy, the mechanism of action and the biopharmacological evaluation of multipotent ligands exhibiting monoamine oxidase (MAO) inhibition as the core activity with a potential for the treatment of NDs. In particular, MAO inhibitors exhibiting additional acetylcholinesterase (AChE) or nitric oxide synthase (NOS) inhibition, or ion chelation/antioxidant-radical scavenging/anti-inflammatory/A2A receptor antagonist/APP processing modulating activities have been thoroughly examined.
Keywords: Multi-target directed ligands, Monoamine oxidase inhibition, Acetylcholinesterase inhibition, Neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, socioeconomic burden, multi-factorial pathologies, ND, MTDL
Current Medicinal Chemistry
Title: Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Volume: 18 Issue: 30
Author(s): L. Pisani, M. Catto, F. Leonetti, O. Nicolotti, A. Stefanachi, F. Campagna and A. Carotti
Affiliation:
Keywords: Multi-target directed ligands, Monoamine oxidase inhibition, Acetylcholinesterase inhibition, Neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, socioeconomic burden, multi-factorial pathologies, ND, MTDL
Abstract: The socioeconomic burden of multi-factorial pathologies, such as neurodegenerative diseases (NDs), is enormous worldwide. Unfortunately, no proven disease-modifying therapy is available yet and in most cases (e.g., Alzheimer's and Parkinson's disease) the approved drugs exert only palliative and symptomatic effects. Nowadays, an emerging strategy for the discovery of disease-modifying drugs is based on the multi-target directed ligand (MTDL) design, an innovative shift from the traditional approach one-drug-one-target to the more ambitious one-drug-more-targets goal. Herein, we review the discovery strategy, the mechanism of action and the biopharmacological evaluation of multipotent ligands exhibiting monoamine oxidase (MAO) inhibition as the core activity with a potential for the treatment of NDs. In particular, MAO inhibitors exhibiting additional acetylcholinesterase (AChE) or nitric oxide synthase (NOS) inhibition, or ion chelation/antioxidant-radical scavenging/anti-inflammatory/A2A receptor antagonist/APP processing modulating activities have been thoroughly examined.
Export Options
About this article
Cite this article as:
Pisani L., Catto M., Leonetti F., Nicolotti O., Stefanachi A., Campagna F. and Carotti A., Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases, Current Medicinal Chemistry 2011; 18 (30) . https://dx.doi.org/10.2174/092986711797379302
DOI https://dx.doi.org/10.2174/092986711797379302 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Chitosan in Drug Delivery for Treatment of Neurological and
Psychiatric Disorders
Current Pharmaceutical Biotechnology CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Procedure for Identification and Characterization of Drugs Efficient Against Mammalian Prion: From a Yeast-Based Antiprion Drug Screening Assay to In Vivo Mouse Models
Infectious Disorders - Drug Targets Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Lipid Nanocarriers for Neurotherapeutics: Introduction, Challenges, Blood-brain Barrier, and Promises of Delivery Approaches
CNS & Neurological Disorders - Drug Targets Structural Diversity of Neuritogenic Substances and their Application Perspective
Mini-Reviews in Medicinal Chemistry Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Peptide Nucleic Acids (PNA)-DNA Chimeras Targeting Transcription Factors as a Tool to Modify Gene Expression
Current Drug Targets Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer
Mini-Reviews in Medicinal Chemistry Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Targets of 3-Bromopyruvate, A New, Energy Depleting, Anticancer Agent
Medicinal Chemistry Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases
Current Cancer Drug Targets The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Prion Protein Oligomerization
Current Alzheimer Research